- Conditions
- Healthy
- Interventions
- K-001, K-877-ER, CSG452
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 385
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Autoimmune Disorder, Healthy Volunteers
- Interventions
- Rilzabrutinib crystalline form, Rilzabrutinib amorphous form
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Amyotrophic Lateral Sclerosis (Healthy Volunteers)
- Interventions
- SAR443820
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Clinical Pharmacology, Healthy Male Volunteer Study
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
- Interventions
- Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- Belzutifan
- Drug
- Lead sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Infections, Bacterial
- Interventions
- GSK1322322 (mesylate salt) Powder for Injection, GSK1322322 (freebase) tablets, GSK1322322 (mesylate salt) Powder for Oral Solution, GSK1322322 (freebase) tablets FED
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Healthy
- Interventions
- PF-07258669, Itraconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Hollywood, Florida
- Conditions
- Depression, Major Depressive Disorder, Weight Gain, Obesity, Metabolic Syndrome
- Interventions
- Reduction of Ultra-processed foods
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hypertension
- Interventions
- baxdrostat (formerly CIN-107) oral solution
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Interventions
- oral azacitidine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 8
- States / cities
- La Jolla, California • Denver, Colorado • Las Vegas, Nevada + 5 more
- Conditions
- Healthy
- Interventions
- Crizotinib, Esomeprazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cystic Fibrosis
- Interventions
- VNZ/TEZ/D-IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy Participants
- Interventions
- Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP, Laroprovstat/ezetimibe FCDP-slow variant
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Olmsted Syndrome
- Interventions
- KM-023, Placebo
- Drug
- Lead sponsor
- Orvida Pharma (formerly Kamari Pharma)
- Network
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Drug Interaction, Food-drug Interaction
- Interventions
- fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole, fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
- Drug
- Lead sponsor
- Hutchison Medipharma Limited
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Food Preferences, Obesity, Weight Gain
- Interventions
- exposure to healthy labels only, exposure to healthiness information, exposure to physical activity equivalents, exposure to sweetened beverage tax messaging
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,065 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy
- Interventions
- MK-8527, Probenecid, Itraconazole
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- ECC5004
- Drug
- Lead sponsor
- Eccogene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Healthy
- Interventions
- Tersolisib, High-fat Meal, Low-fat Meal
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • San Antonio, Texas
- Conditions
- Healthy
- Interventions
- Palbociclib administered Fasted, Palbociclib administered Fed high calorie, Palbociclib administered Fed low calorie, Palbociclib administered Fed moderate calorie
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- PN 200
- Drug
- Lead sponsor
- POZEN
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Healthy Volunteers
- Interventions
- BMS-986419 DR Capsule, BMS-986419 IR Tablet
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Control Group, Mexico-based NSS FOPL, Brazil-based NSS FOPL
- Interventions
- Experimental : Mexico-based NSS FOPL, Experimental : Brazil-based NSS FOPL
- Other
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 1,068 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia